The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Short- and long-term outcomes of conversion surgery for initially unresectable advanced gastric cancer: A Japanese multicenter retrospective cohort study.
 
Itaru Yasufuku
No Relationships to Disclose
 
Masanori Terashima
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Lilly; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Naoki Takahashi
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yukinori Kurokawa
Honoraria - Astellas Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; MC Medical; Medtronic; MSD; Nippon Kayaku; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Seito Fujibayashi
No Relationships to Disclose
 
Nobuhisa Matsuhashi
Honoraria - Abbott Japan; Alfresa Pharma Corporation; Amco; Asahi Kasei; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; EA Pharma; Eisai; Guardant Health; Gunze Medical; Intuitive Surgical; Johnson & Johnson; Kaken Pharmaceutical; Kyowa Kirin; Lilly Japan; MC Medical; Merck KGaA; Miyarisan pharmaceutical; MSD; Novartis; Olympus Marketing, Inc.; Ono Pharmaceutical; Stryker; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Viatris; Yakult Honsha; Zeria Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); e-NA Biotec Inc. (Inst); Eisai (Inst); EPS Corporation (Inst); EPS Holdings (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Kirin (Inst); MSD K.K (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Shift Zero (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Takeshi Omori
No Relationships to Disclose
 
Yuichi Ito
No Relationships to Disclose
 
Michihiro Ishida
No Relationships to Disclose
 
Yukinori Yamagata
No Relationships to Disclose
 
Takanobu Yamada
Honoraria - BMS; Johnson & Johnson/Janssen; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
 
Takuro Saito
No Relationships to Disclose
 
Atsushi Takeno
No Relationships to Disclose
 
Sho Sato
No Relationships to Disclose
 
Keijiro Sugimura
No Relationships to Disclose
 
Takaki Yoshikawa
Honoraria - Astellas Pharma; AstraZeneca; BMS; Chugai Pharma; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson/Janssen; Medtronic; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - MSD Oncology; TERUMO
Research Funding - Lilly